INMD vs. SLNO, CNMD, BLFS, AXGN, OM, CUTR, LIVN, ITGR, TMDX, and NMRA
Should you be buying InMode stock or one of its competitors? The main competitors of InMode include Soleno Therapeutics (SLNO), CONMED (CNMD), BioLife Solutions (BLFS), AxoGen (AXGN), Outset Medical (OM), Cutera (CUTR), LivaNova (LIVN), Integer (ITGR), TransMedics Group (TMDX), and Neumora Therapeutics (NMRA).
Soleno Therapeutics (NASDAQ:SLNO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
In the previous week, InMode had 8 more articles in the media than Soleno Therapeutics. MarketBeat recorded 15 mentions for InMode and 7 mentions for Soleno Therapeutics. InMode's average media sentiment score of 0.64 beat Soleno Therapeutics' score of 0.04 indicating that Soleno Therapeutics is being referred to more favorably in the media.
Soleno Therapeutics currently has a consensus price target of $55.60, suggesting a potential upside of 18.70%. InMode has a consensus price target of $32.80, suggesting a potential upside of 77.78%. Given Soleno Therapeutics' higher probable upside, analysts clearly believe InMode is more favorable than Soleno Therapeutics.
Soleno Therapeutics has a beta of -1.51, suggesting that its share price is 251% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500.
97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 28.8% of Soleno Therapeutics shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Soleno Therapeutics received 140 more outperform votes than InMode when rated by MarketBeat users. However, 75.12% of users gave InMode an outperform vote while only 71.22% of users gave Soleno Therapeutics an outperform vote.
InMode has a net margin of 38.84% compared to InMode's net margin of 0.00%. Soleno Therapeutics' return on equity of 26.15% beat InMode's return on equity.
Summary
InMode beats Soleno Therapeutics on 11 of the 17 factors compared between the two stocks.
Get InMode News Delivered to You Automatically
Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
